• Manju Latha.Y.B
  • Gowri Sankar. D


: Eprosartan, RP-HPLC, Degradation studies


A simple, rapid and accurate and stability indicating RP-HPLC method was developed for the determination of ramipril in pure and tablet forms. The method showed a linear response for concentrations in the range of 100-500 μg/mL using Acetonitrile: Buffer solution in the ratio (70:30) as the mobile phase with detection at 225 nm and a flow rate of 0.8 mL/min and retention time 2.287min. The value of correlation coefficient, slope and intercept were, 0.999, 9318.72and179702, respectively. The method was validated for precision,recovery, ruggedness and robustness. The drug undergoes degradation under acidic, basic, peroxide and thermal degradation conditions. All the peaks of degraded product were resolved from the active pharmaceutical ingredient with significantly different retention time. As the method could effectively separate the drug from its degradation product, it can be employed as a stabilityindicatingone.

Keywords: Eprosartan, RP-HPLC, Degradation studies.


Goodman and Gilman’s, in: Gilman A G, Rall T W, Nies A S,Taylor P. The Pharmacological Basis of Therapeutics. 11th Ed.Pergamon Press: Oxford; 1996, p. 743.

Eckert H G, Muenscher G, Oekonomopulos R, et al. Aradioimmunoassay for the angiotensin converting enzymeinhibitor ramipril and its active metabolite. Arzeneim, Forsch/Drug research. 1985; 35 (8): 1251–1256.

Bonazzi D, Gotti V, Andrisano V, Cavrini V. Analysis of ACEinhibitors in pharmaceutical dosage forms by derivative UVspectroscopy and liquid chromatography (HPLC). J. Pharm. Biomed. Anal. 1997; 16: 431–438.

Rahman N. and Azmi S.N.H. Kinetic SpectrophotometricMethod for the Determination of Ramipril inPharmaceutical Formulations, AAPS Pharm. Sci. Tech., 6(3),2005, E543â€E551.

Aboulâ€Enein H. Y., Raluca I. S, Jacobus F V. Analysis of severalangiotensinâ€converting enzyme inhibitors usingpotentiometric, enantioselective membrane electrodes. Anal.Lett. 1999; 32: 623–632.

Aboulâ€Enein H Y, Bunaciu A, Bala C, Fleischin S. Enalapril andramipril selective membranes, Anal. Lett.1997; 30: 1999–2008.

Hans H M, Thomas K, Joachim W A. Screening for the Detectionof Angiotensinâ€Converting Enzyme Inhibitors, TheirMetabolites, and AT II Receptor Antagonists. Therap. Drug Monitor. 1998; 20: 706–713.

Sereda K M, Hardman T C, Dilloway M R, Lant A F. Developmentof a Method for the Detection of Angiotensin ConvertingEnzyme Inhibitors Using Electron Captureâ€Gas Chromatography Detection. Anal. Proc. 1993; 30: 371–372.

Aboulâ€Enein H Y, Thiffault C. Determination of ramipril and itsprecursors by reversed phase high performance liquidchromatography, Anal. Lett. 1991; 24: 2217–2224.

Motofumi I, Takeo K, Junichi G, Toshio N, Separation ofRamipril Optical Isomers by Highâ€Performance LiquidChromatography. J. Liq. Chromatogr. 1990; 13: 991–1000.

Zhu. Z. and Vachareau. A. Liquid chromatography massspectrometry method for determination of ramipril and itsactive metabolite ramipril in human plasma, J. Chromatogra. B, 779(2), 2002, 297â€306.



How to Cite

Latha.Y.B, M., and G. Sankar. D. “STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF RAMIPRIL IN PURE AND PHARMACEUTICAL FORMULATION”. Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 8, Sept. 2013, pp. 158-61,